OCEANS

Background

Phase 3, double-blind, placebo-controlled RCT (OCEANS). 484 patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer (progression ≥6 months after platinum-based therapy), measurable disease by RECIST, no prior chemotherapy for recurrent disease, no prior bevacizumab. The rationale was that VEGF-driven angiogenesis contributes to ovarian cancer progression and that bevacizumab, already showing single-agent activity in recurrent disease, could potentiate gemcitabine-carboplatin in the platinum-sensitive setting.

Interventions and follow up

Arm A: Gemcitabine 1,000 mg/m² (days 1 and 8) + carboplatin AUC 4 (day 1) + bevacizumab 15 mg/kg (day 1), every 21 days × 6–10 cycles, then bevacizumab 15 mg/kg q21d until disease progression or unacceptable toxicity
Arm B: Gemcitabine + carboplatin on same schedule + placebo, then placebo maintenance
Primary endpoint: Progression-free survival
mFollow up: 24.0 month

Results

PFS: 12.4 vs 8.4 months, HR 0.484 (95% CI 0.388–0.605), P<.0001
ORR: 78.5% vs 57.4%, P<.0001
OS: 33.6 vs 32.9 months, HR 0.952 (95% CI 0.771–1.176) — not significant

Adverse events

Main adverse events: Grade ≥3 hypertension: 17.4% vs 1.0%. Grade ≥3 proteinuria: 8.5% vs 0.9%. Grade ≥3 thromboembolism: 3.4% vs 1.7%. GI perforation/fistula: 2 patients vs 0. Non-CNS bleeding grade ≥3: 0.4% vs 0%. Myelosuppression rates comparable between arms. Treatment discontinuation due to AEs: 16.0% vs 5.0% (bevacizumab/placebo discontinuation).

Conclusions

Adding bevacizumab to gemcitabine-carboplatin significantly improved PFS (12.4 vs 8.4 months, HR 0.484) and ORR in platinum-sensitive recurrent ovarian cancer, though no OS benefit was observed, likely due to post-study bevacizumab crossover and subsequent therapies.

Key Limitations

Key Limitations: Open-label maintenance phase (patients unblinded after chemotherapy completion). No OS benefit despite significant PFS improvement — a finding common to bevacizumab trials in ovarian cancer, attributed to post-progression treatment crossover and the availability of PARP inhibitors as subsequent therapy after the trial was conducted. The PFS benefit magnitude (~4 months) must be weighed against the toxicity profile of prolonged bevacizumab and cost. No biomarker (BRCA, HRD status) stratification — the trial predated molecular classification of ovarian cancer. AURELIA (platinum-resistant setting) and ICON7/GOG-0218 (frontline) provide complementary bevacizumab data in ovarian cancer.

Clinical Context

OCEANS established bevacizumab + gemcitabine-carboplatin as an option for platinum-sensitive recurrent ovarian cancer. However, the landscape has shifted substantially: PARP inhibitors (olaparib, niraparib, rucaparib) are now the standard maintenance therapy in BRCA-mutated and HRD-positive disease, with bevacizumab + PARP inhibitor combinations (PAOLA-1: olaparib+bevacizumab) offering further benefit in frontline HRD-positive disease. Bevacizumab-based regimens remain relevant for patients not receiving PARP inhibitor maintenance or those with BRCA wild-type/HRD-negative disease.

References

References: Aghajanian C et al, JCO 2012 (OCEANS primary)